


PHARMACEUTICAL 2021

RENOVARO BIOSCIENCES INC. Rank 21 of 402







PHARMACEUTICAL 2021

RENOVARO BIOSCIENCES INC. Rank 21 of 402

The relative strengths and weaknesses of RENOVARO BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RENOVARO BIOSCIENCES INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 194% points. The greatest weakness of RENOVARO BIOSCIENCES INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 242% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	8,941
Cost of Goods Sold	0
Intangible Assets	11,717
Liabilities, Current	1,335
Liabilities, Non-Current	1,532
Other Assets	156,665
Other Compr. Net Income	0
Other Expenses	109
Other Liabilities	8,963
Other Net Income	507
Other Revenues	0
Property and Equipment	778
Research and Development	4,694
Selling, General and Administrative Expense	7,121

Output Variable	Value in 1000 USD
Assets	178,102
Liabilities	11,830
Expenses	11,924
Revenues	0
Stockholders Equity	166,272
Net Income	-11,416
Comprehensive Net Income	-11,416
Economic Capital Ratio	289%

